Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02466425 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: SHP465
DRUG: Placebo

Sponsor

Shire